These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24727531)

  • 1. Oligonucleotide-based therapy for neurodegenerative diseases.
    Magen I; Hornstein E
    Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides in therapy for neurodegenerative disorders.
    Evers MM; Toonen LJ; van Roon-Mom WM
    Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense technologies have a future fighting neurodegenerative diseases.
    Seidman S; Eckstein F; Grifman M; Soreq H
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets.
    Klim JR; Vance C; Scotter EL
    Int J Biochem Cell Biol; 2019 May; 110():149-153. PubMed ID: 30904737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide therapy for neurodegenerative disease.
    Smith RA; Miller TM; Yamanaka K; Monia BP; Condon TP; Hung G; Lobsiger CS; Ward CM; McAlonis-Downes M; Wei H; Wancewicz EV; Bennett CF; Cleveland DW
    J Clin Invest; 2006 Aug; 116(8):2290-6. PubMed ID: 16878173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
    Alkhouri N; Reddy GK; Lawitz E
    Hepatology; 2021 Apr; 73(4):1581-1593. PubMed ID: 32978989
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
    Ling H
    Adv Exp Med Biol; 2016; 937():229-37. PubMed ID: 27573903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.
    Schoch KM; Miller TM
    Neuron; 2017 Jun; 94(6):1056-1070. PubMed ID: 28641106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide therapeutics in neurodegenerative diseases.
    Scoles DR; Pulst SM
    RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.
    Mehta M; Deeksha ; Tewari D; Gupta G; Awasthi R; Singh H; Pandey P; Chellappan DK; Wadhwa R; Collet T; Hansbro PM; Kumar SR; Thangavelu L; Negi P; Dua K; Satija S
    Chem Biol Interact; 2019 Aug; 308():206-215. PubMed ID: 31136735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases.
    Southwell AL; Skotte NH; Bennett CF; Hayden MR
    Trends Mol Med; 2012 Nov; 18(11):634-43. PubMed ID: 23026741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.
    Bajan S; Hutvagner G
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases.
    Wu P; Zuo X; Deng H; Liu X; Liu L; Ji A
    Brain Res Bull; 2013 Aug; 97():69-80. PubMed ID: 23756188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of Antisense Drugs.
    Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense Drugs Make Sense for Neurological Diseases.
    Bennett CF; Kordasiewicz HB; Cleveland DW
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.